Talphera, Inc.TLPHNASDAQ

Overview Intelligence Charts News Fundamentals

Latest News

prnewswire.com

Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial

Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sites Company to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring nephrologists, Dr. Blaithin McMahon and Dr. Joao Teixeira SAN MATEO, Calif., March 2, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced 50% patient enrollment of the NEPHRO-CRRT clinical trial.

defenseworld.net

Insider Buying: Talphera (NASDAQ:TLPH) Insider Acquires $28,350.00 in Stock

Talphera, Inc. (NASDAQ: TLPH - Get Free Report) insider Shakil Aslam purchased 35,000 shares of the company's stock in a transaction dated Thursday, February 12th. The stock was bought at an average price of $0.81 per share, with a total value of $28,350.00. Following the completion of the transaction, the insider directly owned 83,178 shares of

defenseworld.net

Talphera (NASDAQ:TLPH) Insider Purchases $28,350.00 in Stock

Talphera, Inc. (NASDAQ: TLPH - Get Free Report) insider Badri Dasu purchased 35,000 shares of the business's stock in a transaction on Thursday, February 12th. The shares were purchased at an average cost of $0.81 per share, for a total transaction of $28,350.00. Following the transaction, the insider owned 76,230 shares of the company's stock, valued

defenseworld.net

Insider Buying: Talphera (NASDAQ:TLPH) CFO Buys $36,450.00 in Stock

Talphera, Inc. (NASDAQ: TLPH - Get Free Report) CFO Raffi Asadorian acquired 45,000 shares of the company's stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average cost of $0.81 per share, for a total transaction of $36,450.00. Following the acquisition, the chief financial officer owned 91,256 shares in

defenseworld.net

Talphera (NASDAQ:TLPH) Shares Down 0.3% – Here’s What Happened

Talphera, Inc. (NASDAQ: TLPH - Get Free Report)'s share price fell 0.3% on Thursday. The company traded as low as $0.7808 and last traded at $0.8079. 39,878 shares traded hands during trading, a decline of 77% from the average session volume of 173,561 shares. The stock had previously closed at $0.81. Analysts Set New Price

defenseworld.net

Talphera (NASDAQ:TLPH) Stock Price Down 2.7% – Here’s Why

Talphera, Inc. (NASDAQ: TLPH - Get Free Report)'s stock price fell 2.7% during trading on Monday. The company traded as low as $1.04 and last traded at $1.07. 189,221 shares were traded during trading, a decline of 55% from the average session volume of 416,292 shares. The stock had previously closed at $1.10. Analysts Set

seekingalpha.com

Talphera, Inc. (TLPH) Q3 2025 Earnings Call Transcript

Talphera, Inc. ( TLPH ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - CEO & Director Shakil Aslam - Chief Medical Officer Conference Call Participants Nazibur Rahman - Maxim Group LLC, Research Division Presentation Operator Welcome to the Talphera Third Quarter 2025 Financial Results Conference Call. This call is being webcast live via the Events page of the Investors section of Talphera's website at www.Talphera.com.

prnewswire.com

Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late 2026 5 of the 9 target profile clinical sites are now activated; completion of NEPHRO study expected in H1 2026 Conference call and webcast to be held Wednesday, November 12, 2025 at 4:30 pm ET SAN MATEO, Calif. , Nov. 12, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2025 financial results and provided a corporate update.

prnewswire.com

Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025

SAN MATEO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2025 financial results after market close on Wednesday, November 12, 2025, then host a live webcast and conference call at 4:30 p.m.

defenseworld.net

Talphera, Inc. (NASDAQ:TLPH) Given Consensus Rating of “Buy” by Brokerages

Shares of Talphera, Inc. (NASDAQ: TLPH - Get Free Report) have been given an average rating of "Buy" by the five research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a buy recommendation and two have given a strong buy

prnewswire.com

Talphera Announces the Appointment of Joe Todisco to Board of Directors

SAN MATEO, Calif. , Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (Nasdaq: CRMD) to its Board of Directors.

globenewswire.com

CorMedix Announces Strategic Minority Investment in Talphera

BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (Nasdaq: TLPH), acquiring 9,090,909 shares at an at-market price of $0.55 per share as part of Talphera's concurrently announced private placement financing.

prnewswire.com

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one additional tranche upon the achievement of the primary endpoint in the NEPHRO clinical study The completion of this financing is expected to provide the company with sufficient capital through the planned approval of a Niyad PMA in the second half of 2026 SAN MATEO, Calif. , Sept. 8, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has entered into securities purchase agreements with CorMedix Inc. and certain institutional investors for the sale and issuance of shares of common stock and pre-funded warrants in lieu of shares to purchase common stock in a private placement for total potential proceeds of up to $29 million.

prnewswire.com

Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial

The NEPHRO CRRT pivotal trial has now reached approximately 25% enrollment, driven by the recent acceleration in the recruitment rate from new profile clinical sites On track for planned study completion by the end of 2025 SAN MATEO, Calif. , Aug. 25, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the enrollment of 17 patients in its 70-patient pivotal NEPHRO CRRT clinical trial.

seekingalpha.com

Talphera, Inc. (TLPH) Q2 2025 Earnings Call Transcript

Talphera, Inc. (NASDAQ:TLPH ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Raffi Mark Asadorian - Chief Financial Officer Shakil Aslam - Chief Medical Officer Vincent J. Angotti - CEO & Director Conference Call Participants Antonio Eduardo Arce - WestPark Capital, Inc. James Francis Molloy - Alliance Global Partners, Research Division Nazibur Rahman - Maxim Group LLC, Research Division Operator Welcome to the Talphera Second Quarter 2025 Financial Results Conference Call.

prnewswire.com

Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update

New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the end of the year Cash and cash equivalents at June 30, 2025 were $6.8 million Conference call and webcast to be held Thursday, August 14, 2025 at 4:30 pm ET SAN MATEO, Calif. , Aug. 14, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2025 financial results and provided a corporate update.

prnewswire.com

Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025

SAN MATEO, Calif. , Aug. 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2025 financial results after market close on Thursday, August 14, 2025, then host a live webcast and conference call at 4:30 p.m.

seekingalpha.com

Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

Talphera, Inc. (NASDAQ:TLPH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Shakil Aslam - Chief Medical Officer Conference Call Participants Operator Welcome to the Talphera First Quarter 2025 Financial Results Conference Call. This call is being webcast live via the Events page of the Investors section of Talphera's website at www.talphera.com.

prnewswire.com

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million Three new clinical study sites activated and screening patients thus far in 2025, with five additional sites expected by mid-year, for a total of 13 Conference call and webcast to be held Wednesday, May 14, 2025 at 4:30 pm ET SAN MATEO, Calif. , May 14, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2025 financial results and provided a corporate update.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance